company background image
5242

Lactose (India) BSE:524202 Stock Report

Last Price

₹89.55

Market Cap

₹1.1b

7D

12.1%

1Y

142.7%

Updated

09 Aug, 2022

Data

Company Financials
524202 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance2/6
Financial Health3/6
Dividends0/6

524202 Stock Overview

Lactose (India) Limited manufactures and trades in pharmaceutical products in India.

Lactose (India) Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Lactose (India)
Historical stock prices
Current Share Price₹89.55
52 Week High₹96.35
52 Week Low₹33.10
Beta-0.12
1 Month Change20.93%
3 Month Change27.84%
1 Year Change142.68%
3 Year Change281.06%
5 Year Change-43.52%
Change since IPO15,610.53%

Recent News & Updates

Shareholder Returns

524202IN PharmaceuticalsIN Market
7D12.1%0.5%1.0%
1Y142.7%-14.2%8.0%

Return vs Industry: 524202 exceeded the Indian Pharmaceuticals industry which returned -14.2% over the past year.

Return vs Market: 524202 exceeded the Indian Market which returned 8% over the past year.

Price Volatility

Is 524202's price volatile compared to industry and market?
524202 volatility
524202 Average Weekly Movement7.7%
Pharmaceuticals Industry Average Movement5.9%
Market Average Movement6.6%
10% most volatile stocks in IN Market9.2%
10% least volatile stocks in IN Market4.3%

Stable Share Price: 524202 is not significantly more volatile than the rest of Indian stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: 524202's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1991103Atul Maheshwarihttps://www.lactoseindialimited.com

Lactose (India) Limited manufactures and trades in pharmaceutical products in India. The company offers lactose monohydrate; dry granulated, film, and lacquer coated tablets; and pharmaceutical products in liquid dose forms. It also provides disaccharide lactulose, an active pharmaceutical ingredient that is used in the treatment of constipation, hepatitis encephalopathy, intestinal microflora, dental care, diabetes, and chronic liver disease, as well as for use as a prebiotic.

Lactose (India) Fundamentals Summary

How do Lactose (India)'s earnings and revenue compare to its market cap?
524202 fundamental statistics
Market Cap₹1.13b
Earnings (TTM)₹24.51m
Revenue (TTM)₹459.39m

46.0x

P/E Ratio

2.5x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
524202 income statement (TTM)
Revenue₹459.39m
Cost of Revenue₹87.40m
Gross Profit₹371.99m
Other Expenses₹347.48m
Earnings₹24.51m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

Aug 09, 2022

Earnings per share (EPS)1.95
Gross Margin80.98%
Net Profit Margin5.34%
Debt/Equity Ratio104.3%

How did 524202 perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is 524202 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 524202?

Other financial metrics that can be useful for relative valuation.

524202 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue3.3x
Enterprise Value/EBITDA12.5x
PEG Ration/a

Price to Earnings Ratio vs Peers

How does 524202's PE Ratio compare to its peers?

524202 PE Ratio vs Peers
The above table shows the PE ratio for 524202 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average36.1x
524790 Everest Organics
100.9xn/a₹1.2b
524506 Coral Laboratories
9.9xn/a₹898.3m
VAISHALI Vaishali Pharma
19.8xn/a₹936.0m
506128 Parnax Lab
13.7xn/a₹1.1b
524202 Lactose (India)
46xn/a₹1.1b

Price-To-Earnings vs Peers: 524202 is expensive based on its Price-To-Earnings Ratio (46x) compared to the peer average (36.1x).


Price to Earnings Ratio vs Industry

How does 524202's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?

Price-To-Earnings vs Industry: 524202 is expensive based on its Price-To-Earnings Ratio (46x) compared to the Indian Pharmaceuticals industry average (21.8x)


Price to Earnings Ratio vs Fair Ratio

What is 524202's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

524202 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio46x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 524202's Price-To-Earnings Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of 524202 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 524202 (₹89.55) is trading above our estimate of fair value (₹81.28)

Significantly Below Fair Value: 524202 is trading above our estimate of fair value.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Future Growth

How is Lactose (India) forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


18.8%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Lactose (India) has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Discover growth companies

  • Take a look at our analysis of 524202’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • Lactose (India) competitive advantages and company strategy can generally be found in its financial reports archived here.

Past Performance

How has Lactose (India) performed over the past 5 years?

Past Performance Score

2/6

Past Performance Score 2/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-39.2%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 524202 has high quality earnings.

Growing Profit Margin: 524202 became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: 524202's earnings have declined by 39.2% per year over the past 5 years.

Accelerating Growth: 524202 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: 524202 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.5%).


Return on Equity

High ROE: 524202's Return on Equity (6.2%) is considered low.


Discover strong past performing companies

Financial Health

How is Lactose (India)'s financial position?

Financial Health Score

3/6

Financial Health Score 3/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: 524202's short term assets (₹227.5M) exceed its short term liabilities (₹149.1M).

Long Term Liabilities: 524202's short term assets (₹227.5M) do not cover its long term liabilities (₹360.3M).


Debt to Equity History and Analysis

Debt Level: 524202's net debt to equity ratio (99.4%) is considered high.

Reducing Debt: 524202's debt to equity ratio has reduced from 128.8% to 104.3% over the past 5 years.

Debt Coverage: 524202's debt is well covered by operating cash flow (20.7%).

Interest Coverage: 524202's interest payments on its debt are not well covered by EBIT (1.6x coverage).


Balance Sheet


Discover healthy companies

Dividend

What is Lactose (India) current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate 524202's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 524202's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 524202's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 524202's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as 524202 has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

6.3yrs

Average management tenure


CEO

Atul Maheshwari (57 yo)

8.58yrs

Tenure

₹9,578,000

Compensation

Mr. Atul Surajmal Maheshwari, MBA, has been Independent Non–Executive Director at Photoquip India Limited since November 11, 2019. He has been Managing Director of Lactose (India) Ltd., since January 24, 2...


CEO Compensation Analysis

Compensation vs Market: Atul's total compensation ($USD120.39K) is above average for companies of similar size in the Indian market ($USD37.79K).

Compensation vs Earnings: Atul's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: 524202's management team is seasoned and experienced (6.3 years average tenure).


Board Members

Experienced Board: 524202's board of directors are seasoned and experienced ( 12.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10.1%.


Top Shareholders

Company Information

Lactose (India) Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Lactose (India) Limited
  • Ticker: 524202
  • Exchange: BSE
  • Founded: 1991
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: ₹1.127b
  • Shares outstanding: 12.59m
  • Website: https://www.lactoseindialimited.com

Number of Employees


Location

  • Lactose (India) Limited
  • Unit No. G-02
  • A Wing, Ground Floor
  • Mumbai
  • Maharashtra
  • 400015
  • India

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/09 00:00
End of Day Share Price2022/08/08 00:00
Earnings2022/03/31
Annual Earnings2022/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.